Anticoagulant treatment with rivaroxaban in severe protein S deficiency

Pediatrics

Volumn 132, Issue 5, 2013, Pages

  Martinelli, Ida ^a   Bucciarelli, Paolo ^a   Artoni, Andrea ^a   Fossali, Emilio F ^a   Passamonti, Serena M ^a   Tripodi, Armando ^a   Peyvandi, Flora ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Anticoagulant; Coagulation; Protein s; Rivaroxaban

Indexed keywords

HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROTEIN S; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; MORPHOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

ANTICOAGULANT THERAPY; ARTICLE; ARTIFICIAL VENTILATION; CASE REPORT; CATHETER THROMBOSIS; CHILD; CLINICAL FEATURE; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; FEMALE; HETEROZYGOSITY; HUMAN; INTUBATION; LUNG EMBOLISM; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN S DEFICIENCY; PROTHROMBIN TIME; RECURRENT DISEASE; SKIN NECROSIS; BLOOD; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ANTICOAGULANTS; CHILD; FACTOR XA INHIBITORS; FEMALE; HUMANS; MORPHOLINES; PROTEIN S DEFICIENCY; SEVERITY OF ILLNESS INDEX; THIOPHENES; TREATMENT OUTCOME;

EID: 84887114247     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2013-1156     Document Type: Article

References (16)

1. Price VE, Ledingham DL, Krümpel A, Chan AK. Diagnosis and management of neonatal purpura fulminans. Semin Fetal Neonatal Med. 2011;16(6):318-322.
2. Veldman A, Fischer D, Wong FY, et al. Human protein C concentrate in the treatment of purpura fulminans: A retrospective analysis of safety and outcome in 94 pediatric patients. Crit Care. 2010;14(4):R156.
3. Bucciarelli P, Passamonti SM, Biguzzi E, et al. Low borderline plasma levels of antithrombin, protein C and protein S are risk factors for venous thromboembolism. J Thromb Haemost. 2012;10(9):1783-1791.
4. Samama MM, Amiral J, Guinet C, Perzborn E, Depasse F. An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma. Thromb Haemost. 2010;104(5):1078-1079.
5. Chantarangkul V, Clerici M, Bressi C, Giesen PL, Tripodi A. Thrombin generation assessed as endogenous thrombin potential in patients with hyper- or hypo-coagulability. Haematologica. 2003;88(5):547-554. (Pubitemid 36648444)
6. Gandrille S, Borgel D, Eschwege-Gufflet V, et al. Identification of 15 different candidate causal point mutations and three polymorphisms in 19 patients with protein S deficiency using a scanning method for the analysis of the protein S active gene. Blood. 1995;85(1):130-138.
7. Dahlbäck B, Stenflo J. A natural anticoagulant pathway: proteins C, S, C4b-binding protein and thrombomodulin. In: Forbes CD, Duncan PT, Tuddenham EGD, eds. Haemostasis and Thrombosis. Vol. 1. 3rd ed. Bloom, AL: Churchill Livingstone; 1994:671-698.
8. Broekmans AW, Bertina RM, Reinalda-Poot J, et al. Hereditary protein S deficiency and venous thrombo-embolism. A study in three Dutch families. Thromb Haemost. 1985;53(2): 273-277.
9. Dykes AC, Walker ID, McMahon AD, Islam SI, Tait RC. A study of Protein S antigen levels in 3788 healthy volunteers: influence of age, sex and hormone use, and estimate for prevalence of deficiency state. Br J Haematol. 2001;113(3):636-641. (Pubitemid 32524382)
10. Fox BD, Kahn SR, Langleben D, Eisenberg MJ, Shimony A. Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: Direct and adjusted indirect meta-analysis of randomised controlled trials. BMJ. 2012;345:e7498 doi: 10.1136/bmj.37498.
11. Hermans C, Eeckhoudt S, Lambert C. Dabigatran etexilate (Pradaxa®) for preventing warfarin-induced skin necrosis in a patient with severe protein C deficiency. Thromb Haemost. 2012;107(6):1189-1191.
12. Esmon CT. The regulation of natural anticoagulant pathways. Science. 1987;235(4794): 1348-1352. (Pubitemid 17041653)
13. Chan MY, Lin M, Lucas J, et al. Plasma proteomics of patients with non-valvular atrial fibrillation on chronic anti-coagulation with warfarin or a direct factor Xa inhibitor. Thromb Haemost. 2012;108(6): 1180-1191.
14. Mueck W, Borris LC, Dahl OE, et al. Population pharmacokinetics and pharmacodynamics of once- And twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost. 2008;100(3): 453-461.
15. Monagle P, Chan AKC, Goldenberg NA, et al; American College of Chest Physicians. Antithrombotic therapy in neonates and children. Chest. 2012;141(suppl 2):e737S-e801S.
16. Makris M, Van Veen JJ, Tait CR, Mumford AD, Laffan M; British Committee for Standards in Haematology. Guideline on the management of bleeding in patients on antithrombotic agents. Br J Haematol. 2013;160(1):35-46.